NeuroAudit

Company Overview

Snapshot

Founded in February 2016 by Dan Anzyo, NeuroAudit operates with 1–10 employees. The company has raised $200,000 across one funding round, focusing on developing neuro stimulus neurotechnology for brain disorders.

Business overview

NeuroAudit is a Health Tech & Life Sciences company specializing in neuro stimulus neurotechnology. The company develops non-invasive solutions, including a cognitive boost patch, for the treatment of brain disorders such as Alzheimer's disease and other cognitive impairments. Their core technology utilizes a unique algorithm to transmit a pure signal through a skin-attached patch, continuously monitoring brain states and controlling real-time stimulation. NeuroAudit's technology has demonstrated improvements in cognitive operations and the ability to send pure tones to deaf individuals via blood conduction using an ultrasonic algorithm, serving the medical devices and medical treatment & therapeutics sectors.

Company Intelligence Q&A

When was NeuroAudit founded?

NeuroAudit was founded in February 2016.

What is NeuroAudit's primary focus?

NeuroAudit focuses on developing neuro stimulus neurotechnology and neuromodulation protocols for personalized brain disease treatment, including a cognitive boost patch for Alzheimer's and cognitive disorders.

What is the core technology behind NeuroAudit's products?

NeuroAudit's core technology involves a non-invasive device that transmits a pure signal through a patch attached to the skin, based on blood conduction directly to the brain using a unique algorithm.

What is the total funding raised by NeuroAudit?

NeuroAudit has raised a total of $200,000 across one seed funding round.

What are some potential applications of NeuroAudit's technology?

Beyond treating brain disorders, NeuroAudit's technology has potential applications in creating new brain-hearing senses to expand the human brain's hearing range and using specific modulations to enhance an individual's level of cognition.